拜玛林制药

Amicus Therapeutics

BioMarin Q4 rev. down YoY; proposes acquisition of Amicus Therapeutics.

Biomarin

BioMarin reports FY14 Talazoparib Research Program revenue down 42% YoY to $15.6mln.

BioMarin Acquires Prosensa, Combines Financial Statements.

Veeva Systems

BioMarin Pharmaceutical Expands Partnership with Veeva Systems, Demonstrates Strong Financial Health, and Shows Undervaluation

Biomarin's 15-minute chart shows MACD Death Cross and KDJ Death Cross

Catalyst<ul> <li>Fundamental factors such as revenue relative to market value and improved operating revenue growth suggest underlying financial strength for BMRN.</li></ul>Risk<ul> <li>Technical indicators show a weak market state with bearish signals dominating, increasing the risk of further decline.</li> <li>Analyst ratings for BMRN are split, with only one Strong Buy rating and two Neutral ratings, indicating mixed institutional expectations.</li></ul>

Key Factors

BioMarin proposes acquisition of Amicus Therapeutics to expand its rare disease treatment portfolio.

Recent Updates

BMRN News